



# IMP761, a novel anti-LAG-3 agonist antibody for the treatment of auto-immune diseases

Mathieu Angin, Ph.D., Immutep Ltd

Copenhagen, March 7 2019




# IMP761 vs Auto-immune diseases: Mode of action

• Current therapies: fighting the symptoms by treating inflammation (e.g. anti-TNF)

• Future direction: fighting the root cause of auto-immune diseases (activation of anti-self

T cells)




#### IMP761 (anti-LAG-3 agonist):

- Down-regulates TCR signaling
- Blocks the activation of self-reactive memory T cells






### **IMP761 Inhibits human T cell proliferation** and activation in vitro




**Proliferation of** (CFSElow) CD8+ T cells



50.5%

**Activation of** (CD25+) CD8+ T cells



Mean of inhibition 38.3%




Proliferation to CEF (CMV + influenza + EBV peptides)




# Delayed-type hypersensitivity model in cynomolgus monkey

#### **Study Design**



#### **Immunofluorescence staining**

Inflammatory T cells infiltration at Tuberculin test site before and after **IMP761/PBS** injection







## IMP761 inhibits inflammatory T cell infiltration


#### T cell infiltration

Inflammatory T cell infiltration at tuberculin site injection before compared to after treatment





#### **Multivariate analysis**



IMP761 is able to inhibit significantly T cell infiltration of an antigen-specific intradermal reaction





### **Conclusions**

**IMP761** 

- The Goal: a more targeted therapeutic approach for AID
- The Target: the self-peptide-specific "exhausted" memory T cells harboring LAG-3
- The Tool: IMP761, an agonistic LAG-3-specific mAb down-modulating selfpeptide-induced TCR signaling
- The Evidence:
  - in vitro inhibition of peptide-induced human T cell proliferation and activation
  - in vivo down-modulation of an antigen-induced inflammatory T cell infiltration in a new NHP model
- The Status: CHO cell line development for GMP manufacturing ongoing in order to progress to clinical development

